These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19719975)

  • 1. Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents.
    Yang WY; Ji QH; Zhu DL; Yang JK; Chen LL; Liu ZM; Yu DM; Yan L
    Chin Med J (Engl); 2009 Jul; 122(14):1704-8. PubMed ID: 19719975
    [No Abstract]   [Full Text] [Related]  

  • 2. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes.
    Bebakar WM; Chow CC; Kadir KA; Suwanwalaikorn S; Vaz JA; Bech OM;
    Diabetes Obes Metab; 2007 Sep; 9(5):724-32. PubMed ID: 17593237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Currie CJ; Evans M; Poole CD
    Diabetes Obes Metab; 2008 Jan; 10(1):94-5. PubMed ID: 18095951
    [No Abstract]   [Full Text] [Related]  

  • 5. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y;
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal.
    Kapitza C; Rave K; Ostrowski K; Heise T; Heinemann L
    Diabet Med; 2004 May; 21(5):500-1. PubMed ID: 15089801
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
    Ebato C; Shimizu T; Arakawa M; Mita T; Fujitani Y; Watada H; Kawamori R; Hirose T
    Diabetes Res Clin Pract; 2009 Oct; 86(1):31-6. PubMed ID: 19692134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premixed biphasic insulin analogs - a choice for pediatric patients with type 2 diabetes rather than type 1 diabetes?
    Danne T
    Pediatr Diabetes; 2006 Feb; 7(1):1-3. PubMed ID: 16489967
    [No Abstract]   [Full Text] [Related]  

  • 10. [Insulin or insulin + oral hypoglycemic drugs in the treatment of type 2 diabetes difficult to compensate metabolically?].
    Carta Q; Trovati M; Dani F; Caselle MT; Vitali S; Cavalot F; Rocca G; Cantino G; Mularoni E; Libertucci D
    Minerva Endocrinol; 1984; 9(2):241-5. PubMed ID: 6390138
    [No Abstract]   [Full Text] [Related]  

  • 11. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J
    Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Insulin and oral antidiabetic drugs. How to combine them in type 2 diabetes?].
    Lotz N
    MMW Fortschr Med; 2000 May; 142(18):45-8. PubMed ID: 10851870
    [No Abstract]   [Full Text] [Related]  

  • 13. Biphasic insulin aspart 30 treatment improves glycemic control among patients with type 2 diabetes in Saudi Arabia and the Gulf region.
    Ayad NM; Fattah WA; Bakry H
    Saudi Med J; 2008 Jun; 29(6):919-20. PubMed ID: 18521482
    [No Abstract]   [Full Text] [Related]  

  • 14. Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
    Currie CJ; McEwan P; Poole C; Valentine WJ; Palmer AJ; Lammert M; Nicklasson L; Foos V; Roze S
    Curr Med Res Opin; 2006 May; 22(5):967-9; author reply 968-9. PubMed ID: 16709318
    [No Abstract]   [Full Text] [Related]  

  • 15. How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?
    Koenen C
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):E1. PubMed ID: 18806804
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
    Thorisdottir RL; Parkner T; Chen JW; Ejskjaer N; Christiansen JS
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin glargine: cornerstone treatment for type 2 diabetes patients. Introduction.
    Garg SK
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():1-4. PubMed ID: 18577151
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients.
    Ballani P; Tran MT; Navar MD; Davidson MB
    Diabetes Care; 2006 Nov; 29(11):2504-5. PubMed ID: 17065692
    [No Abstract]   [Full Text] [Related]  

  • 19. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus.
    Crasto W; Jarvis J; Hackett E; Nayyar V; McNally PG; Davies MJ; Lawrence IG
    Postgrad Med J; 2009 Apr; 85(1002):219-22. PubMed ID: 19417173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe insulin allergy after percutaneous transluminal coronary angioplasty.
    Wang C; Ding ZY; Shu SQ; Liu Y; Chen YC; Ran XW; An ZM; Tian HM; Tong NW; Li XJ; Yu YR
    Clin Ther; 2009 Mar; 31(3):569-74. PubMed ID: 19393846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.